Up next
Share article
The post has been shared by 0 people.
Mail 0
LinkedIn 0
Twitter 0

How Will the Pharma Industry Perform in 2024 & the Near Term?

With 2024 well underway, the crucial question for both bio/pharma companies and their suppliers is: how will the industry perform in 2024 and the near term? Get the answer to that all-important question at the Pharma Industry Outlook education program at DCAT Week.

With 2024 well underway, the crucial question for both bio/pharma companies and their suppliers is: how will the industry perform in 2024 and the near term? Get the answer to that all-important question at the Pharma Industry Outlook education program at DCAT Week.

Getting the latest market analysis and data

Graham Lewis 
Vice President, Global Pharma Strategy 
IQVIA

What are the key growth indicators for the global bio/pharmaceutical market in 2024 and over the next several years, and how will the industry perform over this time?  That is the trillion-dollar question for the bio/pharma industry.

DCAT Week’s flagship program, Pharma Industry Outlook, will answer that question by providing valuable market intelligence on the current and projected performance of the bio/pharma industry. Graham Lewis, Vice President of Global Pharma Strategy, IQVIA, a business intelligence firm regarded as the gold standard for bio/pharma market analysis, will provide the latest market data and trends.

COVID-19 vaccines and therapeutics had been a boon for the industry, but with lower growth for these products, how will the industry perform relative to pre-pandemic growth trends? Is the industry’s performance trending upward or not? The program will examine the growth prospects and factors influencing performance for: innovator and generic drugs; leading therapeutic sectors, both pipelines and commercial products; and developed and emerging markets.

Daniel Cohen 
Managing Director & Global Head of Pharma Outsourcing Investment Banking
Morgan Stanley

A CMDO/CMO financial outlook
The performance of the industry as a whole is a factor in determining the health of the market for pharmaceutical outsourcing, which is further influenced by other factors. The program will also feature a Wall Street view of the CDMO/CMO sector, with Daniel Cohen, Managing Director & Global Head of Pharma Outsourcing Investment Banking, Morgan Stanley, providing a financial overview of the CDMO/CMO sector: performance & investor valuations. He will provide an analysis of key mergers & acquisitions and other trends impacting sector performance.

Pharma Industry Outlook will be held at the InterContinental Barclay Hotel, Grand Ballroom on Monday, March 18, 2023: 2:30 – 4:30 PM; Doors open at 2:00 PM for pre-program networking. Plus, Post-Program Attendee Networking Reception: 4:30 to 6:00 PM. 

Information on the program, including how to register, may be found here.

Recent Feature Articles

The Battle of the Blockbusters: GLP-1 Agonists

By
GLP-1 agonist drugs, in the form of Novo Nordisk’s Wegvoy/Ozempic, and Lilly’s Mounjaro for weight management and treating Type II diabetes, were blockbuster winners in 2023, putting this therapeutic sector into high focus. What has been the impact on manufacturing and what are other contenders in this high-growth sector?

Manufacturing & Supply Lines: Small-Molecule APIs

By
Small-molecule drugs still dominate new drug approvals, as measured by the number of new molecular entities approved by the FDA’s Center for Drug Evaluation and Research, but are they translating into market success? DCAT Value Chain Insights takes a look on the market for drugs with small-molecule active pharmaceutical ingredients and related supply–demand fundamentals.

European Parliament Takes Next Step in Reforming EU Pharma Legislation

By
The European Parliament adopted its positions on proposals to revamp the EU‘s pharmaceutical legislation, which includes measures impacting drug development, commercialization, manufacturing & the supply chain. European innovator & generic-drug companies weigh in.

What’s Trending: Generic Drugs by the Numbers & Key Market Developments

By
Generic-drug approvals in the US reached a recent high in 2023 although the number of first-generic approvals were down comparative to recent years. DCAT Value Chain Insights takes a look inside the numbers and the key market moves from the leading generic-drug companies.